Millions across the world have a tough journey with Chronic Kidney Disease (CKD). It often leads to life-altering complications and costly medical interventions. But a wave of hope has just swept in with the U.S. The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets. This treatment transforms the landscape of treatments available for adults with CKD at risk of progression.
Jardiance®: A Beacon for Many
Developed by Boehringer Ingelheim and Eli Lilly and Company, Jardiance® has emerged as a welcome solution. It’s specifically tailored for adults with CKD. However, it’s important to note that it’s not suitable for everyone. Those with polycystic kidney disease or those who have recently received intravenous immunosuppressive therapy, might not receive a successful outcome.
#NEWS: Together with @EliLillyandCo, we are happy to share that Jardiance® (empagliflozin) has received @US_FDA approval for the treatment of adults with #ChronicKidneyDisease (CKD), following the recent approval by the @EU_Commission! https://t.co/hAvhL7fYHu— Boehringer Ingelheim (@Boehringer) September 22, 2023
Groundbreaking Results: The EMPA-KIDNEY Trial
The journey of Jardiance® to approval was marked by the positive outcomes in the EMPA-KIDNEY phase III trial. Participants, coming from diverse backgrounds, experienced a significant 28% relative risk reduction. This is for the combined primary endpoint of kidney disease progression or cardiovascular death compared to a placebo. Such remarkable findings highlight the potential impact of Jardiance® in addressing the challenges posed by CKD.
A Global Promise
This FDA approval is not just a win for the United States but represents a global stride forward. Jardiance® has also received approval for CKD in the EU. It is the fourth indication for Jardiance®, solidifying its role in combating cardio-renal-metabolic conditions. It extends a helping hand to communities worldwide.
More than a Medical Achievement
Katherine Tuttle, M.D., Executive Director for Research at Providence Inland Northwest Health, shared her optimism about Jardiance. She reflects on how it offers a meaningful new treatment avenue that can significantly ease the burdens of CKD. This includes kidney function drop and cardiovascular complications.
Similarly, Mohamed Eid, M.D., M.P.H., M.H.A., from Boehringer Ingelheim Pharmaceuticals, Inc., emphasized the profound implications of Jardiance®’s approval. This is considering the high prevalence and significant healthcare costs associated with CKD-related hospitalizations.
Humanizing the Impact
For every individual silently battling CKD, the approval of Jardiance® brings hope and the possibility of a better quality of life. It also represents the triumph of strict scientific search over a debilitating disease that has impacted the lives of millions worldwide.
In a world often overpowered by the silent struggle with CKD, Jardiance® stands out as a beacon. It is lighting the way toward hope, resilience, and a better tomorrow for all affected by this condition.